CN107207613A - 含Toll样受体胞内结构域的嵌合抗原受体 - Google Patents

含Toll样受体胞内结构域的嵌合抗原受体 Download PDF

Info

Publication number
CN107207613A
CN107207613A CN201580000296.XA CN201580000296A CN107207613A CN 107207613 A CN107207613 A CN 107207613A CN 201580000296 A CN201580000296 A CN 201580000296A CN 107207613 A CN107207613 A CN 107207613A
Authority
CN
China
Prior art keywords
cell
receptor
intracellular domain
toll
chimeric antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580000296.XA
Other languages
English (en)
Other versions
CN107207613B (zh
Inventor
李鹏
赖允鑫
林思妙
姚瑶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen In Vivo Biomedicine Technology Ltd
Original Assignee
Shenzhen In Vivo Biomedicine Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen In Vivo Biomedicine Technology Ltd filed Critical Shenzhen In Vivo Biomedicine Technology Ltd
Publication of CN107207613A publication Critical patent/CN107207613A/zh
Application granted granted Critical
Publication of CN107207613B publication Critical patent/CN107207613B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了一种嵌合抗原受体、其编码核酸和表达细胞，以及其在制备治疗肿瘤的药物中的用途。所述嵌合抗原受体的胞内结构域至少包括Toll样受体1和/或Toll样受体2的胞内结构域。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201580000296.XA 2015-08-07 2015-08-07 含Toll样受体胞内结构域的嵌合抗原受体 Active CN107207613B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/086352 WO2017024440A1 (zh) 2015-08-07 2015-08-07 含Toll样受体胞内结构域的嵌合抗原受体

Publications (2)

Publication Number Publication Date
CN107207613A true CN107207613A (zh) 2017-09-26
CN107207613B CN107207613B (zh) 2020-06-09

Family

ID=57983214

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580000296.XA Active CN107207613B (zh) 2015-08-07 2015-08-07 含Toll样受体胞内结构域的嵌合抗原受体

Country Status (6)

Country Link
US (1) US10093717B2 (zh)
EP (1) EP3202792A4 (zh)
CN (1) CN107207613B (zh)
AU (1) AU2015376656B2 (zh)
NZ (1) NZ722076A (zh)
WO (1) WO2017024440A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108486062A (zh) * 2018-03-23 2018-09-04 深圳市体内生物医药科技有限公司 一种嵌合抗原受体免疫细胞及其制备方法和应用
CN109734813A (zh) * 2019-01-28 2019-05-10 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106834228B (zh) * 2017-01-17 2021-03-23 上海新长安生物科技有限公司 一种体外扩增cd8+t细胞及其细胞亚群的方法
WO2019067328A1 (en) 2017-09-26 2019-04-04 Cero Therapeutics, Inc. CHIMERIC ENGINEERING RECEPTOR MOLECULES AND METHODS OF USE
CN109517799B (zh) * 2018-11-30 2022-07-26 北京美康基免生物科技有限公司 一种基于cd19和cd22的双重嵌合抗原受体基因修饰的免疫细胞及其应用
CN112226412B (zh) * 2020-10-12 2023-05-02 汤朝阳 一种表达免疫抑制检查点受体分子的t细胞及其应用
CN113527521B (zh) * 2020-12-14 2022-05-31 广州百暨基因科技有限公司 一种抗b7h3嵌合抗原受体及其应用
US20240082300A1 (en) * 2021-01-15 2024-03-14 National University Corporation Tokai National Higher Education And Research System Chimeric target factor receptor
CN113501885B (zh) * 2021-07-20 2023-02-24 中国农业大学 嵌合抗病基因及其相关生物材料与应用
WO2023056296A1 (en) * 2021-09-29 2023-04-06 Vita Therapeutics, Inc. Methods and compositions for treating cancer with engineered cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104087607A (zh) * 2013-04-01 2014-10-08 上海益杰生物技术有限公司 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞
WO2014172584A1 (en) * 2013-04-17 2014-10-23 Baylor College Of Medicine IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104087607A (zh) * 2013-04-01 2014-10-08 上海益杰生物技术有限公司 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞
WO2014172584A1 (en) * 2013-04-17 2014-10-23 Baylor College Of Medicine IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLANDINE C. MERCIER等: "TLR2 Engagement on CD8 T Cells Enables Generation of Functional Memory Cells in Response to a Suboptimal TCR Signal", 《THE JOURNAL OF IMMUNOLOGY》 *
GIANPIETRO DOTTI等: "Design and Development of Therapies using Chimeric Antigen Receptor-Expressing T cells", 《IMMUNOL REV.》 *
Y LAI等: "Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells", 《LEUKEMIA》 *
YUE GUAN等: "Human TLRs 10 and 1 Share Common Mechanisms of Innate Immune Sensing but Not Signaling", 《THE JOURNAL OF IMMUNOLOGY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108486062A (zh) * 2018-03-23 2018-09-04 深圳市体内生物医药科技有限公司 一种嵌合抗原受体免疫细胞及其制备方法和应用
CN109734813A (zh) * 2019-01-28 2019-05-10 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
CN109734813B (zh) * 2019-01-28 2022-06-17 广东昭泰体内生物医药科技有限公司 一种嵌合抗原受体及其应用
US11713348B2 (en) 2019-01-28 2023-08-01 Guangdong Zhaotai Invivo Biomedicine Co., Ltd ScFv amino acid sequence, chimeric antigen receptor containing same and application thereof

Also Published As

Publication number Publication date
US10093717B2 (en) 2018-10-09
EP3202792A4 (en) 2018-02-21
WO2017024440A1 (zh) 2017-02-16
CN107207613B (zh) 2020-06-09
AU2015376656B2 (en) 2018-01-04
NZ722076A (en) 2019-11-29
US20170233454A1 (en) 2017-08-17
AU2015376656A1 (en) 2017-02-23
EP3202792A1 (en) 2017-08-09

Similar Documents

Publication Publication Date Title
CN107207613A (zh) 含Toll样受体胞内结构域的嵌合抗原受体
RU2670147C1 (ru) Вектор экспрессии car и car-экспрессирующие т-клетки
JP6639233B2 (ja) Ｍａｇｅ−ａ１を認識する高結合活性結合分子
EP2651442B1 (en) Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
AU2015218239B2 (en) Chimeric antigen receptors and methods of making
Tang et al. T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo
CN105377897A (zh) Cs1-特异性嵌合抗原受体工程化的免疫效应细胞
WO2019061562A1 (zh) 一种增强t细胞抗肿瘤活性的核酸分子
CN109414428A (zh) 靶向血液恶性肿瘤之嵌合抗原受体（car），其组合物及使用方法
CN109734813A (zh) 一种嵌合抗原受体及其应用
CN104780939A (zh) 用于细胞免疫治疗的方法和组合物
CN106536564A (zh) 靶向cd‑19的嵌合抗原受体
CN108218999A (zh) 分泌il-7的嵌合抗原受体、病毒载体、表达细胞及制备方法与药物
CN109776671A (zh) 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用
CN110305906A (zh) 一种靶向pdl1的car嵌合受体的慢病毒载体及pdl1-car-t细胞
CN110511912A (zh) 免疫细胞的功能调节
CN107624119B (zh) 一种分子、表达其的细胞及其制备方法和用途
CN109824783A (zh) 表达于t淋巴细胞表面的嵌合抗原受体及其应用
CN113493525B (zh) 一种增效且抵抗耗竭的嵌合抗原受体t细胞及其在制备治疗肿瘤药物中的用途
US20220280564A1 (en) Methods for expanding t cells for the treatment of cancer and related malignancies
CN111996170B (zh) 基因工程化的nk细胞、其制备方法和用途
CN108864276A (zh) 靶向ny-eso-1的t细胞受体联合表达pd1抗体可变区及其用途
CN115279792A (zh) 对bcma特异的抗体及嵌合抗原受体
CN116034113A (zh) 一种增强型t细胞受体star及其应用
CN111875710A (zh) 异质性肿瘤治疗用免疫细胞及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant